Empagliflozin Treatment in Kidney Transplant Recipients

Summary

Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Kidney Transplant
• Chronic Kidney Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

19 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

VA Office of Research and Development

Last updated on ClinicalTrials.gov

April 21, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites